


Contents

ON THE COVER



Nonalcoholic Fatty Liver Disease (NAFLD) Gets Renamed as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Progress But With Challenges. See article by Allen, et al, page 229 for additional information.

COMMENTARIES

- 229** **Nonalcoholic Fatty Liver Disease Gets Renamed as Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress But With Challenges**
A. M. Allen, E. Pose, K. R. Reddy, M. W. Russo, and P. S. Kamath

DIVERSITY, EQUITY, AND INCLUSION IN GI

- 235** **Pharmacoequity for Older Adults With Inflammatory Bowel Diseases**
B. Kochar, A. N. Ananthakrishnan, and C. S. Ritchie

MENTORING, EDUCATION, AND TRAINING CORNER

- 240** **A Practical Guide to Evaluating and Using Big Data in Digestive Disease Research**
M. Alizadeh, N. Sampaio Moura, A. Schledwitz, S. A. Patil, H. El-Serag, J. Ravel, and J.-P. Raufman

EDITORIALS

- 248** **Toward Quantification of *H pylori*-associated Gastric Cancer Risk: Further Evidence Supporting Development of Population-based Strategies for *H pylori* Eradication**
A. C. Ford and D. Y. Graham
See Yoo HW et al on page 313.
- 250** **Too Much of a Good Thing: Imposing an Upper Limit to a High Fiber Diet**
J. M. S. Lemons
See Yang J et al on page 323.

GASTRO CURBSIDE CONSULT

- 252** **A Chain Reaction to Dysphagia**
J. Issa, N. Nassani, and F. Bazerbachi

Video Related article in CGH Hot Papers From New Investigators

CME quiz Editorial accompanies this article Additional online content available Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2024 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

- 255 **An Unusual Cause of Small Bowel Obstruction**
W. Lu, L. Yang, and J. D. Schulberg

ELECTRONIC GASTRO CURBSIDE CONSULT

For a full list, please see the table of contents online at www.gastrojournal.org.

GASTRO GRAND ROUNDS

- 259 **A 68-Year-Old Woman With Unexplained Liver Enzyme Elevation and Active Chronic Hepatitis: Beware of Drug-Induced Autoimmune-Like Hepatitis**
L. Dara, M. Ghabril, E. Phillips, D. Kleiner, and N. Chalasani

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

- 267 **Evolving Concepts in *Helicobacter pylori* Management**
S. F. Moss, S. C. Shah, M. C. Tan, and H. B. El-Serag

ORIGINAL RESEARCH

Full Reports

GI Cancer

- 284 **p21 Prevents the Exhaustion of CD4⁺ T Cells Within the Antitumor Immune Response Against Colorectal Cancer**
O.-M. Thoma, E. Naschberger, M. Kubánková, I. Larafa, V. Kramer, B. Menchicchi, S. Merkel, N. Britzen-Laurent, A. Jefremow, R. Grützmann, K. Koop, C. Neufert, R. Atreya, J. Guck, M. Stürzl, M. F. Neurath, and M. J. Waldner
Gate-keeper p21 is important for preventing cluster of differentiation 4-positive T-cell exhaustion in colorectal cancer. Targeting the cell cycle machinery in cluster of differentiation 4-positive T cells might improve their antitumor response.
- 298 **An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies**
M. C. Hasselluhn, D. Schlösser, L. Versemann, G. E. Schmidt, M. Ulisse, J. Oswald, Z. Zhang, F. Hamdan, H. Xiao, W. Kopp, J. Spitalieri, C. Kellner, C. Schneider, K. Reutlinger, S. Nagarajan, B. Steuber, S. A. Sastra, C. F. Palermo, J. Appelhans, H. Bohnenberger, J. Todorovic, I. Kostyuchek, P. Ströbel, A. Bockelmann, A. König, C. Ammer-Herrmann, L. Schmidleitner, S. Kaulfuß, B. Wollnik, S. A. Hahn, A. Neesse, S. K. Singh, H. Bastians, M. Reichert, U. Sax, K. P. Olive, S. A. Johnsen, G. Schneider, V. Ellenrieder, and E. Hessmann
Evidence is provided for a combinatory therapeutic approach with specific efficacy in a molecularly characterized subgroup of pancreatic cancer patients.
- 313 ***Helicobacter pylori* Treatment and Gastric Cancer Risk After Endoscopic Resection of Dysplasia: A Nationwide Cohort Study**
H. W. Yoo, S. J. Hong, and S. H. Kim
See editorial on page 248.

This large-scale study found that treating *Helicobacter pylori* may reduce the risk of developing stomach cancer in patients who have undergone endoscopic removal of gastric dysplasia.

Gut Microbiota

- 323 **High Soluble Fiber Promotes Colorectal Tumorigenesis Through Modulating Gut Microbiota and Metabolites in Mice**
J. Yang, H. Wei, Y. Lin, E. S. H. Chu, Y. Zhou, H. Gou, S. Guo, H. C. H. Lau, A. H. K. Cheung, H. Chen, K. F. To, J. J. Y. Sung, Y. Wang, and J. Yu
See editorial on page 250.

The authors identified that soluble but not insoluble fiber promotes colorectal tumorigenesis in a dose-dependent manner through modulating gut microbiota and metabolites in mice.

RESEARCH LETTERS

- 338** **Texture and Color Enhancement Imaging Improves Colonic Adenoma Detection: A Multicenter Randomized Controlled Trial**
E. Young, A. Rajagopalan, D. Tee, D. Sathanathan, S. Hoile, and R. Singh

- 341** **Alcohol Drinking Without Meals Is Associated With Risk of Gastrointestinal Cancers, Including Early-Onset Cases**
M. Shi, N. J. Ahmedin, X. Zong, Ö. H. Yilmaz, F. Bishehsari, and Y. Cao

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

- e19** **CME Exam 1: A 68-Year-Old Woman With Unexplained Liver Enzyme Elevation and Active Chronic Hepatitis: Beware of Drug-Induced Autoimmune-Like Hepatitis**
- e22** **CME Exam 2: Alcohol Drinking Without Meals Is Associated With Risk of Gastrointestinal Cancers, Including Early-Onset Cases**

CLINICAL PRACTICE UPDATES

- 345** **AGA Clinical Practice Update on Endoscopic Full-Thickness Resection for the Management of Gastrointestinal Subepithelial Lesions: Commentary**
L. S. D'Souza, D. Yang, and D. Diehl

GASTRO DIGEST

- 350** **Survival in Unresectable Hepatocellular Carcinoma Treated With a New Immune Checkpoint and Anti-angiogenic Drug Combination**
C. Mezzacappa
- 350** **Efficacy of Computer-Aided Polyp Detection in Randomized Trials**
N. Forbes
- 351** **Could Gut and Food-Derived Yeast Be Responsible for Activating T Cells in Crohn's Disease?**
E. Wine
- 352** ***Helicobacter pylori* Genetic Variations: A Driver of Gastric Cancer Progression?**
E. J. Muruaga and N. L. Jones

CORRESPONDENCE

- 353** **Toward the Understanding of Altered Gut Microbiome in Crohn's Disease: Cause or Consequence**
S. Gao, R. Zhu, and L. Zhu
- 354** **Investigating the Causal Relationship Between Gut Microbiota and Crohn's Disease: A Mendelian Randomization Study**
Z. Li, Y. Chen, and H. Ke
- 355** **Reply**
W. Turpin, S.-H. Lee, and K. Croitoru
- 356** **Comments on "Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study"**
S. He, Y. Peng, and Q. Wei
- 357** **Reply**
A. J. Yarur and P. Deepak

- 358 Enhancing Colorectal Cancer Screening Specificity by Integrating Fecal MicroRNA Signature With Fecal Immunochemical Test and Fecal Occult Blood Test**
A. Noursina and F. Safari
- 358 Reply**
B. Pardini, G. Ferrero, and A. Naccarati
- 359 Medicare Part D Spending for Hepatitis B Virus Drugs: Completing the Picture and Extending the Dataset**
S. E. Congly, M. Brahmania, and C. S. Coffin
- 361 Reply**
X. Ying and A. B. Jesudian
- 361 Surgical Resection Might Be the Preferred Therapy Option in Ileocecal Crohn's Disease**
M. Kelm and S. Flemming
- 362 First-Line Treatment Options for Ileocecal Crohn's Disease: Early Surgical Resection or Biologics?**
F. Yan and Y. Yang
- 363 Reply**
M. Agrawal, J.-F. Colombel, and K. H. Allin

Access to the full content of Gastroenterology Online is available to all subscribers!

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology* Online. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology* Online will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology* Online are for individual use only and may not be transferred. Use of *Gastroenterology* Online is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number

Your Account Number

Sample mailing label

GAST0000101864
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001

1GAST V91-4 1234567-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001